The activation of FXR by CDCA or GW4064 negatively interferes with enzymes UGT2B15 and UGT2B17, two major determinants of the androgen response in prostate cancer cells, without affecting cell viability [140]. This evidence concerns the gene NR1H4 and prostate carcinoma.